Suppression of autophagy enhances preferential toxicity of paclitaxel to folliculin-deficient renal cancer cells

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Zhang, Qi ^a,b   Si, Shuhui ^b   Schoen, Sue ^b   Chen, Jindong ^b   Jin, Xun Bo ^a   Wu, Guan ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Autophagy; BHD; FLCN; Folliculin; Kidney cancer; Paclitaxel; Taxol

Indexed keywords

3 METHYLADENINE; BECLIN 1; ESTRONE; PACLITAXEL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; ASSAY; AUTOPHAGY; CANCER CELL; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; FOLLICULIN DEFICIENT RENAL CANCER CELL; MTT ASSAY; NICK END LABELING; PRIORITY JOURNAL; STAIN; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRONE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KIDNEY NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; PACLITAXEL; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84888770323     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-99     Document Type: Article

References (31)

1. Autophagy and apoptosis: what is the connection? Gump JM, Thorburn A, Trends Cell Biol 2011 21 387 392 10.1016/j.tcb.2011.03.007 21561772
2. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G, Nat Rev Mol Cell Biol 2007 8 741 752 17717517 (Pubitemid 47312826)
3. Autophagy and cancer. Mah LY, Ryan KM, Cold Spring Harb Perspect Biol 2012 4 008821 22166310
4. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Katayama M, Kawaguchi T, Berger MS, Pieper RO, Cell Death Differ 2007 14 548 558 10.1038/sj.cdd.4402030 16946731
5. Role and regulation of autophagy in cancer. Chen N, Karantza-Wadsworth V, Biochim Biophys Acta 2009 1793 1516 1523 10.1016/j.bbamcr.2008.12.013 19167434
6. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Scripture CD, Figg WD, Sparreboom A, Ther Clin Risk Manage 2005 1 107 114 10.2147/tcrm.1.2.107.62910
7. Effect of autophagy inhibition on chemotherapy-induced apoptosis in A549 lung cancer cells. Liu F, Liu D, Yang Y, Zhao S, Oncol Lett 2013 5 1261 1265 23599776
8. Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells. Kim HJ, Lee SG, Kim YJ, Park JE, Lee KY, Yoo YH, et al. Int J Oncol 2013 42 1985 1992 23563171
9. The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Veldhoen RA, Banman SL, Hemmerling DR, Odsen R, Simmen T, Simmonds AJ, et al. Oncogene 2013 32 736 746 10.1038/onc.2012.92 22430212
10. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene. Lu X, Wei W, Fenton J, Nahorski MS, Rabai E, Reiman A, et al. Mol Cancer Ther 2011 10 80 89 21220493
11. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Birt AR, Hogg GR, Dube WJ, Arch Derm 1977 113 1674 1677 10.1001/archderm.1977.01640120042005 596896 (Pubitemid 8241734)
12. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, et al. J Natl Cancer Inst 2008 100 140 154 10.1093/jnci/djm288 18182616 (Pubitemid 351480566)
13. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, et al. PLoS One 2008 3 3581 10.1371/journal.pone.0003581 18974783
14. Gene expression and protein array studies of folliculin-regulated pathways. Reiman A, Lu X, Seabra L, Boora U, Nahorski MS, Wei W, et al. Anticancer Res 2012 32 4663 4670 23155228
15. Activation of AMP-activated protein kinase by MAPO1 and FLCN induces apoptosis triggered by alkylated base mismatch in DNA. Lim TH, Fujikane R, Sano S, Sakagami R, Nakatsu Y, Tsuzuki T, et al. DNA Repair (Amst) 2012 11 259 266 10.1016/j.dnarep.2011.11.006 22209521
16. The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dube syndrome is required for murine B-cell development. Baba M, Keller JR, Sun HW, Resch W, Kuchen S, Suh HC, et al. Blood 2012 120 1254 1261 10.1182/blood-2012-02-410407 22709692
17. Folliculin contributes to VHL tumor suppressing activity in renal cancer through regulation of autophagy. Bastola P, Stratton Y, Kellner E, Mikhaylova O, Yi Y, Sartor MA, et al. PLoS One 2013 8 70030 10.1371/journal.pone.0070030 23922894
18. Targeting androgen receptor leads to suppression of prostate cancer via induction of autophagy. Jiang Q, Yeh S, Wang X, Xu D, Zhang Q, Wen X, et al. J Urol 2012 188 1361 1368 10.1016/j.juro.2012.06.004 22906664
19. How to interpret LC3 immunoblotting. Mizushima N, Yoshimori T, Autophagy 2007 3 542 545 17611390 (Pubitemid 350060049)
20. Menzies FM, Moreau K, Puri C, Renna M, Rubinsztein DC, Measurement of autophagic activity in mammalian cells USA: John Wiley & Sons, Inc Current protocols in cell biology / editorial board, Juan S Bonifacino et al. 2012 Chapter 15:Unit 15-16
21. Guidelines for the use and interpretation of assays for monitoring autophagy. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Autophagy 2012 8 445 544 10.4161/auto.19496 22966490
22. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Biederbick A, Kern HF, Elsasser HP, Eur J Cell Biol 1995 66 3 14 7750517
23. Dioscin-induced autophagy mitigates cell apoptosis through modulation of PI3K/Akt and ERK and JNK signaling pathways in human lung cancer cell lines. Hsieh MJ, Tsai TL, Hsieh YS, Wang CJ, Chiou HL, Arch Toxicol 2013 87 11 1927 1937 10.1007/s00204-013-1047-z 23552851
24. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. Liu Y, Yang Y, Ye YC, Shi QF, Chai K, Tashiro S, et al. J Pharmacol Sci 2012 118 423 432 10.1254/jphs.11181FP 22466960
25. Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma. Sfoungaristos S, Giannitsas K, Perimenis P, Expert Opin Pharmacother 2011 12 533 547 10.1517/14656566.2011.524928 21306289
26. Integrating innovative therapeutic strategies into the management of renal cell carcinoma. Dutcher JP, Mourad WF, Ennis RD, Oncology (Williston Park) 2012 26 526 530 32, 34 22870536
27. Recent advances in the systemic treatment of metastatic papillary renal cancer. Chowdhury S, Choueiri TK, Expert Rev Cardiovasc Ther 2009 9 373 379
28. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, et al. Med Oncol 2012 29 761 767 10.1007/s12032-011-9829-8 21298497
29. The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dube gene pathway. Yang Y, Padilla-Nash HM, Vira MA, Abu-Asab MS, Val D, Worrell R, et al. Cancer Genet Cytogenet 2008 180 100 109 10.1016/j.cancergencyto.2007.10.010 18206534
30. Network organization of the human autophagy system. Behrends C, Sowa ME, Gygi SP, Harper JW, Nature 2010 466 68 76 10.1038/nature09204 20562859
31. Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells. Wu S, Wang X, Chen J, Chen Y, Biochem Biophys Res Commun 2013 434 898 903 10.1016/j.bbrc.2013.04.053 23624503